SynthesisMultiple sclerosis (Houndmills, Basingstoke, England)2015
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review.
Synthesis in Multiple sclerosis (Houndmills, Basingstoke, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Pooled it
- A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.Journal of neurology · 2021Pooled it
- A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Pooled it
- Comorbid autoimmune diseases do not influence long-term disability progression in multiple sclerosis.Acta neurologica Belgica · 2026Article
- Allergic phenotypes and asthma in multiple sclerosis: Epidemiologic and genetic relationships.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Complications and Risk Factors of Neurogenic Bladder: A Delphi Consensus.European urology open science · 2026Article
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system.International journal of clinical pharmacy · 2026Article
- Bladder and Bowel Management in Adolescents and Young Adults with Multiple Sclerosis Since Childhood: Is Bowel Management Overlooked? A Case Series.Children (Basel, Switzerland) · 2026Article
- Comorbidity and modifiable risk factors in multiple sclerosis.Therapeutic advances in neurological disorders · 2026Review
- Symptoms Prior to Diagnosis of Multiple Sclerosis in Individuals Younger Than 18 Years.JAMA network open · 2024Article
- Interstitial Cells of Cajal and Enteric Nervous System in Gastrointestinal and Neurological Pathology, Relation to Oxidative Stress.Current issues in molecular biology · 2023Review
- Comorbidity in the aging population with multiple sclerosis: a Danish nationwide study.Frontiers in neurology · 2023Article
- Comorbid disease burden among MS patients 1968-2012: A Swedish register-based cohort study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Change and onset-type differences in the prevalence of comorbidities in people with multiple sclerosis.Journal of neurology · 2021Article
- Influence of Comorbidities on Healthcare Expenditures and Perceived Physical and Mental Health Status Among Adults with Multiple Sclerosis: A Propensity Score-Matched US National-Level Study.ClinicoEconomics and outcomes research : CEOR · 2021Article
- Article
- Comorbidity in Multiple Sclerosis.Frontiers in neurology · 2020Review
- Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes.Journal of clinical medicine · 2019Review
- Multi-drug use among patients with multiple sclerosis: A cross-sectional study of associations to clinicodemographic factors.Scientific reports · 2019Article
- Impact of delayed treatment on exacerbations of multiple sclerosis among Puerto Rican patients.Surgical neurology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
Abstract
backgroundAs new disease-modifying therapies emerge a better knowledge of the risk of comorbid disease in multiple sclerosis (MS) is needed.
objectiveTo estimate the incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in MS.
methodsWe systematically reviewed the world literature by searching PUBMED, EMBASE, SCOPUS, the Web of Knowledge, and reference lists of retrieved articles. For selected articles, one reviewer abstracted data using a standardized form. The abstraction was verified by a second reviewer. The quality of all selected studies was assessed. For population-based studies we quantitatively assessed studies using the I² statistic, and conducted random effects meta-analyses.
resultsStudy designs were heterogeneous with respect to populations, case definitions, and methods of ascertainment. Incidence of the studied comorbidities was rarely reported. Irritable bowel syndrome and chronic lung disease had a prevalence of more than 10% in the MS population. Irritable bowel syndrome, fibromyalgia, cataracts and glaucoma were more common than expected in the MS population.
conclusionAlthough they have been the subject of less study than other comorbidities, irritable bowel syndrome, arthritis, and chronic lung disease are common in the MS population and occur more often than expected when compared to the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.